Neuropsychiatric Features, Health-Related Quality of Life, and Caregiver Burden in Parkinson's Disease
- PMID: 36911463
- PMCID: PMC9996534
- DOI: 10.4103/aian.aian_38_22
Neuropsychiatric Features, Health-Related Quality of Life, and Caregiver Burden in Parkinson's Disease
Abstract
Aim: Parkinson's disease (PD) is a progressive neurodegenerative disease and significantly impacts patients and their caregivers. The current study aims at recognizing its neuropsychiatric symptoms, its impact on the health-related quality of life (HRQOL) of the patients, and the caregiver burden in a middle- to-low-income country.
Methods: We conducted a cross-sectional survey of 73 idiopathic Parkinson's disease (IPD) patients and their caregivers from January 2021 to June 2021. Neuropsychiatric Inventory (NPI-12) and Parkinson's disease questionnaire (PDQ-39) were used to assess patients' symptoms and HRQOL, respectively. We used the Zarit caregiver burden interview (ZBI) and Hamilton depression scale (Ham-D) for the caregiver's burden assessment.
Results: Of the 73 patients, 43 (59%) were men, and 30 (41%) were women. Their mean age was 60.25 years (± 11.1), and the mean duration of PD was 6.4 years (± 3.4). Eighty-six percent of the patients reported having one or more neuropsychiatric symptoms. HRQOL, as indicated by PDQ-39, correlated most significantly with H and Y staging (r = 0.680, P < 0.001) of the disease. Sixty-eight percent of the caregivers felt a disease burden, and 55% had depression. On regression analysis, NPI total score on caregiver burden (beta = 0.883, P < 0.001, confidence interval [CI] of 1.087 to 1.400,) and H and Y staging on depression (beta = 0.772, P < 0.001, [CI of 0.629 to 0.934) were having the most decisive impact.
Conclusion: Our study showed the presence of frequent neuropsychiatric symptoms in PD patients. It has a detrimental effect on the quality of life of patients and results in a significant increase in caregiver burden and depression among them.
Keywords: Caregiver burden; Parkinson's disease; movement disorders; neuropsychiatric symptoms; quality of life.
Copyright: © 2022 Annals of Indian Academy of Neurology.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Neuropsychiatric Symptoms and Caregiver Burden in Parkinson's Disease.Ann Indian Acad Neurol. 2020 Sep-Oct;23(5):656-660. doi: 10.4103/aian.AIAN_91_20. Epub 2020 Jul 8. Ann Indian Acad Neurol. 2020. PMID: 33623267 Free PMC article.
-
[Effects of sleep quality and mood of patients with Parkinson's disease on their caregivers].Zhonghua Yi Xue Za Zhi. 2020 Nov 24;100(43):3414-3418. doi: 10.3760/cma.j.cn112137-20200225-00444. Zhonghua Yi Xue Za Zhi. 2020. PMID: 33238671 Chinese.
-
Burden and health-related quality of life among caregivers of Brazilian Parkinson's disease patients.Parkinsonism Relat Disord. 2013 Nov;19(11):943-8. doi: 10.1016/j.parkreldis.2013.06.005. Epub 2013 Jul 4. Parkinsonism Relat Disord. 2013. PMID: 23831481
-
Caregiver burden in Parkinson's disease: a mixed-methods study.BMC Med. 2023 Jul 10;21(1):247. doi: 10.1186/s12916-023-02933-4. BMC Med. 2023. PMID: 37424022 Free PMC article.
-
4.2 Burden of disease and quality of life in Parkinson's disase: a role for CDS.In: Odin P, Chaudhuri KR, Aquilonious SM, Mundt-Petersen U, editors. Where are We? Continuous Dopaminergic Stimulation for Parkinson's Disease [Internet]. Berkshire (UK): Empowering Strategic Performance Ltd; 2023 Jan 1. In: Odin P, Chaudhuri KR, Aquilonious SM, Mundt-Petersen U, editors. Where are We? Continuous Dopaminergic Stimulation for Parkinson's Disease [Internet]. Berkshire (UK): Empowering Strategic Performance Ltd; 2023 Jan 1. PMID: 39208176 Free Books & Documents. Review. No abstract available.
Cited by
-
Mild Behavioral Impairment in Parkinson's Disease: An Updated Review on the Clinical, Genetic, Neuroanatomical, and Pathophysiological Aspects.Medicina (Kaunas). 2024 Jan 7;60(1):115. doi: 10.3390/medicina60010115. Medicina (Kaunas). 2024. PMID: 38256375 Free PMC article. Review.
-
Depression in Patients With Parkinson's Disease: A Hospital-Based Cross-Sectional Study.Cureus. 2023 Oct 17;15(10):e47214. doi: 10.7759/cureus.47214. eCollection 2023 Oct. Cureus. 2023. PMID: 38022066 Free PMC article.
-
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerations.J Neural Transm (Vienna). 2023 Nov;130(11):1451-1462. doi: 10.1007/s00702-023-02684-9. Epub 2023 Aug 21. J Neural Transm (Vienna). 2023. PMID: 37603058 Review.
References
-
- Mueller C, Rajkumar AP, Wan YM, Velayudhan L, Ffytche D, Chaudhuri KR, et al. Assessment and management of neuropsychiatric symptoms in Parkinson's disease. CNS Drugs. 2018;32:621–35. - PubMed
-
- Barone P, Erro R, Picillo M. Quality of life and nonmotor symptoms in Parkinson's disease. Int Rev Neurobiol. 2017;133:499–516. - PubMed
-
- Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233–9. - PubMed
-
- Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age Ageing. 1997;26:353–7. - PubMed